XENE ▲ +3.1% - Xenon Pharmaceuticals Inc.
$XENE - Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
29-OCT-2026 08:30 AM ET
Share this post
More filings for $XENE
XENE ▼ -2.5% - Xenon Pharmaceuticals Inc.Oct 2, 2026XENE ▼ -1.8% - Xenon Pharmaceuticals Inc.Sep 21, 2026XENE ▼ -25.4% - Xenon Pharmaceuticals Inc.Sep 18, 2026XENE ▼ -15.4% - Xenon Pharmaceuticals Inc.Sep 17, 2026XENE ▲ +0.1% - Xenon Pharmaceuticals Inc.Sep 3, 2026XENE - Xenon Pharmaceuticals Inc. - SEC Filing Update (13-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 13, 2026
View full $XENE filing history →💬 Comments
Loading comments…
Leave a comment